FATE - Fate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.18
-1.13 (-4.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close23.31
Open22.86
Bid22.05 x 800
Ask22.52 x 2200
Day's Range21.86 - 23.34
52 Week Range12.59 - 32.39
Volume822,965
Avg. Volume1,095,488
Market Cap1.684B
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateMar 01, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.94
  • Thomson Reuters StreetEvents

    Edited Transcript of FATE earnings conference call or presentation 2-Mar-20 10:00pm GMT

    Q4 2019 Fate Therapeutics Inc Earnings Call

  • Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?

    Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

  • The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
    Benzinga

    The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Fate Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter results) * Forty Seven Inc (NASDAQ: FTSV) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO)( announced an accelerated timeline for COVID-19 vaccine development) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 3) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * Akorn, Inc. (NASDAQ: AKRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) * Midatech Pharma PLC-ADR (NASDAQ: MTP)(began trading on a reverse split adjusted basis) * Mylan NV (NASDAQ: MYL) * Neuronetics Inc (NASDAQ: STIM)(announced its fourth-quarter results) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * SurModics, Inc. (NASDAQ: SRDX) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TransMedics Group Inc (NASDAQ: TMDX)(reported its fourth-quarter results) * VIVUS, Inc. (NASDAQ: VVUS) * Xeris Pharmaceuticals Inc (NASDAQ: XERS)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesStocks In Focus Takeda To Develop COVID-19 Treatments Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin to treat high-risk individuals with the viral infection. Hyperimmune globulins are plasma-derived therapies that had previously proven its efficacy in treating severe acute viral respiratory infections.The company added it is also studying its currently marketed and pipeline products to see whether they are effective treatments for infected patients.Separately, the company said it has completed its previously announced sale of portfolio of select products to STADA for $660 million.In pre-market trading Wednesday, Takeda shares were adding 3.94% to $18.20.Vir, Alnylam Expands Collaboration To Develop siRNA Therapies For COVID-19 Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion to their existing collaboration to include the development and commercialization of RNAi therapeutics against COVID-19. The agreement provides for Vir using Alnylam's recent advances in lung delivery of novel conjugates of siRNA along with its infectious disease expertise to develop one or some siRNAs to treat COVID-19 and other coronaviruses as well.In premarket trading Wednesday, Vir share were rallying 14.72% to $47 and Alnylam was edging up 0.41% to $111.88.Mallinckrodt Reports Positive Outcome Analysis of Acthar Gel In Immune-mediated Diseases Mallinckrodt PLC (NYSE: MNK) announced findings from a retrospective medical record analysis, which assessed practice patterns and outcomes of Acthar Gel in the treatment of immune-mediated diseases rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis, which showed across all the three patient populations, symptoms improved with Acthar Gel.In premarket trading Wednesday, the shares were advancing 7.99% $3.38.Acadia's Rett Syndrome Investigational Drug Gets Rare Pediatric Designation ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharma said the FDA has granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.Upon approval of a product with the designation, the sponsor is eligible to receive a Priority Review Voucher, which can be used to obtain FDA approval of an NDA for another product in an expedited period of six months.Acadia shares were up 2.41% to $42.99 in after-hours trading.Morphosys' Licensing Agreement With Incyte For Lymphoma Drug Gets Antitrust Clearance Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said their joint collaboration and license agreement for further development and global commercialization of Morphosys' investigational compound tafasitamab has received antitrust clearance and becomes effective Tuesday.The regulatory milestone triggers a $750 million upfront payment by Incyte to Morphosys, and also Incyte's equity investment of $150 million into MorphoSys within the defined timelines.The PDUFA date for the BLA for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma is Aug. 30.Ultragenyx CFO To Step Down Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) said Shalini Sharp will step down as CFO and EVP, effective Sept. 2. The company said it will initiate a search for a successor.Exact Sciences Buys Two Cancer Diagnostics Companies Exact Sciences said it has completed its acquisition of Paradigm Diagnostics and Viomics, two privately held companies, which provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery.View more earnings on TAKThe company expects the acquisition to extend its lab testing and research and development capabilities.J&J Makes Regulatory Submission For Approval of Multiple Sclerosis Drug In Europe Johnson & Johnson's (NYSE: JNJ) Janssen unit announced it submitted a Marketing Authorization Application to EMA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Earnings DURECT Corporation (NASDAQ: DRRX) reported fourth-quarter net revenues of $10.69 million compared to $3.63 million last year. The net loss per share narrowed from 5 cents to 2 cents, in line with the consensus estimate.The stock jumped 12.21% to $1.93 in after-hours trading.Menlo Therapeutics Inc's (NASDAQ: MNLO), which has agreed to be bought by Foamix Pharmaceuticals Ltd (NASDAQ: FOMX), reported a wider loss of 89 cents per share compared to the year-ago loss of 76 cents per share and the consensus loss estimate of 83 cents per share.Updating on the pending merger, Menlo said it expects it to close March 9.The stock jumped 23.64% to $3.40 in after-hours trading.Voyager Therapeutics Inc (NASDAQ: VYGR) reported fourth quarter revenues of $32.67 million compared to $2.01 million a year ago. The net loss per share narrowed from 77 cents to 34 cents. Analysts had estimated a loss of 81 cents per share. The company said it expects its cash reserves as well as receivables to be sufficient to meet its projected operating expenses and capex into mid-2022.The stock gained 6.22% to $12.30 in after-hours trading.Vivus reported fourth-quarter total revenues of $17.25 million and a loss of 61 cents per share, narrower than the 68 cents per share loss expected by analysts.The stock rose 8.98% to $1.82 in after-hours trading.Offerings Zogenix, Inc. (NASDAQ: ZGNX) said it has priced its underwritten public offering of 8.52 million shares at $23.50 per share. The company expects to raise gross proceeds of $200.2 million from the offering. The offering is expected to close on or about March 6.The company said it expects to use the net proceeds for the potential commercialization of Fintepla for the treatment of Dravet syndrome, among other things.The stock fell 3.69% to $24 in after-hours trading.On The Radar Earnings * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (before the market open) * Recro Pharma Inc (NASDAQ: REPH) (before the market open) * PPD Inc (NASDAQ: PPD) (before the market open) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the close) * Orthopediatrics Corp (NASDAQ: KIDS) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close)See more from Benzinga * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

    Fate Therapeutics (FATE) delivered earnings and revenue surprises of 5.13% and 52.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook
    GlobeNewswire

    Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook

    Reported Initial Clinical Data from FT500 Phase 1 Study in Advanced Solid Tumors, Supporting Safety and Tolerability of Multi-dose Treatment Paradigm for Off-the-shelf,.

  • The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
    Benzinga

    The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

    Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for some biotechs that disclosed plans to work on therapies or vaccines for countering the viral attack.The FDA approved Esperion Therapeutics Inc's (NASDAQ: ESPR) LDL-cholesterol lowering combo therapy and Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) migraine drug.The following are key catalysts that could move biotech stocks in the unfolding week.Conferences Cowen 40th Annual Healthcare Conference: March 2-4 in Boston, MassachusettsView more earnings on IBBRelated Link: Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder DrugEarnings Monday * Albireo Pharma Inc (NASDAQ: ALBO) (before the market open) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) (before the market open) * Intra-Cellular Therapies Inc (NASDAQ: ITCI) (before the market open) * Seres Therapeutics Inc (NASDAQ: MCRB) (before the market open) * Urogen Pharma Ltd (NASDAQ: URGN) (before the market open) * Wave Life Sciences Ltd (NASDAQ: WVE) (before the market open) * Fate Therapeutics Inc (NASDAQ: FATE) (after the close) * FibroGen Inc (NASDAQ: FGEN) (after the close) * GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close) * Omeros Corporation (NASDAQ: OMER) (after the close) * PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close) * Precigen Inc (NASDAQ: PGEN) (after the close) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) (after the close) * Zogenix, Inc. (NASDAQ: ZGNX) (after the close)Tuesday * Antares Pharma Inc (NASDAQ: ATRS) (before the market open) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) (before the market open) * Neuronetics Inc (NASDAQ: STIM) (before the market open) * TG Therapeutics Inc common stock (NASDAQ: TGTX) (before the market open) * Sierra Oncology Inc (NASDAQ: SRRA) (before the market open) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) (after the close) * VIVUS, Inc. (NASDAQ: VVUS) (after the close) * Voyager Therapeutics Inc (NASDAQ: VYGR) (after the close) * DURECT Corporation (NASDAQ: DRRX) (after the close) * Cytokinetics, Inc. (NASDAQ: CYTK) (after the close)Wednesday * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the close) * Orthopediatrics Corp (NASDAQ: KIDS) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close)Thursday * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close)IPO Quiet Period Expiry Beam Therapeutics Inc (NASDAQ: BEAM)PPD Inc (NASDAQ: PPD)Apart from scheduled catalysts, any company updates on COVID-19 programs could be of interest for investors given the potential for big swings.See more from Benzinga * The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy * The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results
    GlobeNewswire

    Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results

    SAN DIEGO, Feb. 26, 2020 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for

    Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Fate Therapeutics to Present at Upcoming Investor Conferences
    GlobeNewswire

    Fate Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, Feb. 07, 2020 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.

  • Steven Cohen Renews His Interest in Verastem
    GuruFocus.com

    Steven Cohen Renews His Interest in Verastem

    Guru invests in restructuring cancer drug developer Continue reading...

  • Fate Therapeutics (NASDAQ:FATE) Shareholders Have Enjoyed A Whopping 682% Share Price Gain
    Simply Wall St.

    Fate Therapeutics (NASDAQ:FATE) Shareholders Have Enjoyed A Whopping 682% Share Price Gain

    Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...

  • Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood
    GlobeNewswire

    Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its second Investigational New Drug (IND) application for FT516, the Company’s off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel CD16 Fc receptor. This is the Company’s fourth IND from its proprietary iPSC product platform cleared by the FDA, and enables the clinical investigation of FT516 in combination with monoclonal antibody (mAb) therapy across a broad range of solid tumors.

  • InvestorPlace

    3 Top Drug Stocks to Own In 2020

    Broadly speaking, drug stocks have been some of the strongest performing names in the latter part of 2019.Since October 2019, the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) has rallied from a low of $96 to nearly $124. The SPDR S&P Biotech ETF (NYSE:XBI) exploded from $75 to a high of $98.79. Even ProShares Ultra NASDAQ Biotechnology (NASDAQ:BIB) popped from a low of $41 to a high of nearly $65.All despite concerns over potential changes to drug pricing policies with elections ahead.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"While we get the sense that biotech investors are cautious into 2020 with the election and broader macro concerns, we believe that macro issues are unlikely to have material fundamental impact," says Credit Suisse's Evan Seigerman.Wedbush analysts argue, "The fundamentals of the sector look strong. Biotech surged in the third quarter, approvals from the Food & Drug Administration are coming through above the average annual rate, the valuation of large-cap biotechs are attractive, and there have been significant mergers and acquisitions in past years."Plus, one of the biggest catalysts for future growth are the millions of retiring baby boomers.We're also seeing new, innovative treatments for a myriad of issues. In addition, such stocks are recession-proof because folks will always require medical attention. * 10 2019 Winners That Will Be 2020 Losers Here are three of the top biotech stocks to watch in the New Year. Top Drug Stocks: Fate Therapeutics (FATE)After struggling out the gate, Fate Therapeutics (NASDAQ:FATE) exploded from a low of $14 to $20 a share after posting positive trial results from its natural kill (NK) cell product candidate.With regards to data from its natural killer (NK) cell product candidate, "Current patient- and donor-specific CAR T-cell immunotherapies recognize only one antigen and fail to address the significant risk of relapse due to antigen escape. FT596 is ground-breaking in that it is designed to be available off-the-shelf for timely patient access and to promote deeper and more durable responses by targeting multiple tumor-associated antigens," said Bob Valamehr, Ph.D., Chief Development Officer of Fate Therapeutics.The company's other natural cell killer was also found to kill off cancer in a patient with acute myeloid leukemia (AML). Wells Fargo recently upgraded the FATE stock to an overweight rating with a target of $24. Axsome Therapeutics (AXSM)Axsome Therapeutics (NASDAQ:AXSM) had an explosive year. Since January 2019, AXSM stock exploded from a low of $2.64 to a recent high of $105.55. All after a series of major announcements, throughout the year. In January, for example, AXSM noted that its lead drug candidate, AXS-05 met its primary endpoint in a Phase II trial for major depressive disorder.Two months later, AXSM won FDA Breakthrough Therapy for the drug. By April, the drug also achieved its primary endpoint for smoking cessation. By December, its AXS-12 drug met its primary endpoint in a Phase II trial targeting narcolepsy.Then just two weeks ago, the AXSM stock ramped higher on news of positive late-state results for AXS-05, as a treatment of major depressive disorder. * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever "Given the documented medical need for more potent MDD therapies, and the fact that a whopping 17 million American adults suffer from this condition every year, according to the National Institutes of Health, this experimental depression med has a clear path toward blockbuster status," noted Motley Fool contributor George Budwell. Pfizer (PFE)Last year wasn't kind to Pfizer (NYSE:PFE) or its shareholders. In late July, PFE plunged 21% on company plans to combine its blockbuster drug-selling unit with Mylan (NYSE:MYL), and announced it was cutting its sales and adjusted earnings forecast.However, with a strong drug portfolio, acquisitions, and an undervalued stock, PFE is attracting interest once again. The company also just raised its dividend by 5.6%, which brings the new quarterly dividend to 38 cents from 36 cents payable March 6, 2020 to shareholders as of Jan. 31.Plus, "the valuation on new Pfizer looks appealing, given management's expectation of 6% annualized sales growth through 2025, which could produce 10%-plus yearly gains in earnings per share. New Pfizer has important patent-protected drugs like Ibrance for breast cancer and the pneumonia vaccine Prevnar, plus a strong pipeline," notes Barron's contributor Andrew Bary.As of this writing, Ian Cooper did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Winners That Will Be 2020 Losers * 5-Year Returns for 5 Dow Jones Stocks Entering 2020 * 5 Semiconductor Stocks to Buy for Big Gains In 2020 The post 3 Top Drug Stocks to Own In 2020 appeared first on InvestorPlace.

  • Thomson Reuters StreetEvents

    Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Fate Therapeutics Inc Earnings Call

  • Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
    Zacks

    Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

    The biotech sector witnesses pipeline updates from the annual ASH meet.

  • Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting
    GlobeNewswire

    Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida. FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D. The Company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.

  • Fate (FATE) Announces Encouraging Data on Immunotherapies
    Zacks

    Fate (FATE) Announces Encouraging Data on Immunotherapies

    Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

  • Company News for Dec 10, 2019
    Zacks

    Company News for Dec 10, 2019

    Companies in the news are: ARQL, THOR, CGC, FATE

  • Here Are The Winners From The Year's Biggest Hematology Meeting
    Investor's Business Daily

    Here Are The Winners From The Year's Biggest Hematology Meeting

    Shares of biotech companies rocketed Monday, led by Forty Seven and Fate, after bullish presentations for cancer and blood-disease drugs at the American Society of Hematology meeting.

  • Benzinga

    Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook

    Update from the annual meeting of the American Society of Hematology (ASH) suggested that initial data for Fate Therapeutics Inc’s (NASDAQ: FATE ) FT500 and FT516 therapies were well received by both clinicians ...

  • Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE)

    Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]

  • Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
    GlobeNewswire

    Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT596, its off-the-shelf, multi-antigen targeting natural killer (NK) cell product candidate derived from a clonal master engineered induced pluripotent stem cell (iPSC) line. The data were featured during the 61st American Society of Hematology (ASH) Meeting and Exposition as part of the organization’s CAR-T and Beyond press program, which spotlighted promising next-generation cancer immunotherapies having the potential to overcome the key limitations of patient-specific chimeric antigen receptor (CAR) T-cell therapy.

  • Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
    GlobeNewswire

    Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

    Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced initial clinical data for its FT516 and FT500 off-the-shelf, iPSC-derived natural killer (NK) cell product candidates. “The safety, tolerability, and immunogenicity data from the Phase 1 dose-escalation stage of FT500, the first-ever cell therapy derived from a clonal master induced pluripotent stem cell line to undergo clinical investigation in the U.S., provide compelling evidence that multiple doses of iPSC-derived NK cells can be delivered off-the-shelf and administered without patient matching,” said Wayne Chu, M.D., Vice President of Clinical Development of Fate Therapeutics.

  • Is Fate Therapeutics (NASDAQ:FATE) A Risky Investment?
    Simply Wall St.

    Is Fate Therapeutics (NASDAQ:FATE) A Risky Investment?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
    GlobeNewswire

    Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 27, 2019 -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular.